Drug
Nateglinide
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Lactic Acidosis | 37 | 18.2 | 18.6 | signal |
| 2 | Diabetes Mellitus Inadequate Control | 14 | 12.4 | 12.6 | signal |
| 3 | Hypoglycaemia | 36 | 11.7 | 12.0 | signal |
| 4 | Blood Glucose Fluctuation | 8 | 11.5 | 11.5 | signal |
| 5 | End Stage Renal Disease | 13 | 11.1 | 11.2 | signal |
| 6 | Blood Potassium Increased | 11 | 10.7 | 10.8 | signal |
| 7 | Nephropathy | 6 | 10.1 | 10.1 | signal |
| 8 | Proteinuria | 12 | 10.0 | 10.1 | signal |
| 9 | Glycosylated Haemoglobin Increased | 15 | 9.4 | 9.5 | signal |
| 10 | Body Height Decreased | 6 | 8.7 | 8.8 | signal |
| 11 | Chronic Kidney Disease | 41 | 8.4 | 8.7 | signal |
| 12 | Myoclonus | 6 | 7.9 | 8.0 | signal |
| 13 | Blood Lactate Dehydrogenase Increased | 8 | 7.9 | 7.9 | signal |
| 14 | Hypothermia | 5 | 7.8 | 7.8 | signal |
| 15 | Blood Glucose Decreased | 22 | 7.2 | 7.3 | signal |
| 16 | Osteomyelitis | 8 | 7.0 | 7.0 | signal |
| 17 | Renal Failure Acute | 19 | 6.9 | 7.0 | signal |
| 18 | Blood Glucose Abnormal | 8 | 6.8 | 6.8 | signal |
| 19 | Glaucoma | 8 | 6.5 | 6.6 | signal |
| 20 | Cerebral Infarction | 10 | 6.4 | 6.5 | signal |
| 21 | Blood Glucose Increased | 76 | 6.3 | 6.6 | signal |
| 22 | Anorexia | 5 | 6.0 | 6.0 | signal |
| 23 | Blood Creatine Phosphokinase Increased | 11 | 5.9 | 6.0 | signal |
| 24 | Renal Injury | 11 | 5.8 | 5.8 | signal |
| 25 | Interstitial Lung Disease | 17 | 5.5 | 5.6 | signal |
| 26 | Multi-organ Failure | 6 | 5.4 | 5.4 | signal |
| 27 | Injection Site Extravasation | 4 | 5.0 | 5.1 | signal |
| 28 | Cytomegalovirus Infection | 5 | 4.7 | 4.7 | signal |
| 29 | Product Taste Abnormal | 4 | 4.7 | 4.7 | signal |
| 30 | Myelodysplastic Syndrome | 4 | 4.3 | 4.4 | signal |
| 31 | Injection Site Nodule | 3 | 4.3 | 4.3 | signal |
| 32 | Product Physical Issue | 5 | 3.9 | 4.0 | signal |
| 33 | Diabetic Ketoacidosis | 6 | 3.9 | 4.0 | signal |
| 34 | Injection Site Haemorrhage | 14 | 2.8 | 2.8 | signal |
| 35 | Gastric Cancer | 4 | 2.5 | 2.5 | no signal |
| 36 | Pancreatic Carcinoma | 4 | 2.2 | 2.2 | no signal |
| 37 | Completed Suicide | 11 | 2.1 | 2.1 | signal |
| 38 | Injection Site Pruritus | 8 | 1.9 | 1.9 | no signal |
| 39 | Bladder Cancer | 6 | 1.6 | 1.6 | no signal |
| 40 | Wrong Technique In Device Usage Process | 3 | 1.0 | 1.0 | no signal |